Medication info

Sevitex Tablet 5/40 mg

Prescription medicationTabletOralExpired
Ingredient · strength
Olmesartan Medoxomil›40mg / 1 tabletAmlodipine Besylate›6.94mg / 1 tablet
Manufacturer / importer
International Pharmaceuticals Co., Ltd.
Appearance
Pale yellow round film-coated tablet
Packaging
30 tablets / box [(10 tablets / PTP × 3)]
Approval status
Expired

MFDS item code 201405095 · Approved 2014.10.31

This product's status changed to Expired on 2024.10.31. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Treatment of essential hypertension
Who takes it
Adults · Children
Adult dose
Take 1 tablet once daily with water, without regard to meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). Before starting this medication, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, switching directly to this medication may be considered if blood pressure is not controlled with monotherapy using an individual component. The maximum dose of this medication is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 mg once daily. Use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with intravascular volume depletion: In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive medications and/or diuretics, blood pressure and renal function should be closely monitored. This medication should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medication under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.
Child dose
The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age.

Ingredients

Manufacturer
International Pharmaceuticals Co., Ltd.

Efficacy & effects

Treatment of essential hypertension

  • Essential hypertension
View approved original text

This medication is used to effectively lower blood pressure in patients with essential hypertension who do not achieve adequate blood pressure control with monotherapy using Amlodipine or Olmesartan Medoxomil. This helps to reduce the risk of cardiovascular disease and improves blood pressure control.

How to take

Adult dose

Take 1 tablet once daily with water, without regard to meals. If possible, it is recommended to take it at the same time every day (e.g., in the morning). Before starting this medication, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, switching directly to this medication may be considered if blood pressure is not controlled with monotherapy using an individual component. The maximum dose of this medication is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medication has not been studied in patients with renal impairment. However, for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min), the maximum dose of olmesartan medoxomil is 20 mg once daily. Use of this medication is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with intravascular volume depletion: In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while closely monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. In patients with hepatic impairment who are already receiving other antihypertensive medications and/or diuretics, blood pressure and renal function should be closely monitored. This medication should not be administered to patients with severe hepatic impairment. (See section 2. Patients who should not receive this medication under Precautions for Use.) ∘Elderly patients: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. In elderly patients, blood pressure should be monitored closely and more frequently.

Child dose

The safety and efficacy of this medication have not been established in pediatric patients under 18 years of age.

Precautions

This drug can cause serious harm to the fetus and newborn if taken during the 2nd and 3rd trimester of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Should not be used in patients with allergy to any component of this drug, those who are pregnant or breastfeeding, and in cases of severe liver impairment, aortic stenosis, bile duct obstruction, or renal dialysis. In patients with fluid or salt depletion, low blood pressure may occur at the start of treatment, so the patient's condition should be carefully monitored. Caution is especially required in severe aortic stenosis patients, as vascular dilation may lead to hypotension. Careful use is needed in patients with severe obstructive coronary artery disease or congestive heart failure, and monitoring for the exacerbation of heart failure is required. Changes in renal function may occur in patients with impaired renal function, therefore caution is needed. Patients with liver impairment may have a slower metabolism for the drug, hence caution is required. This medication may cause side effects such as dizziness, headache, hypotension, edema, nausea, rash, and if symptoms persist, consultation with a physician is recommended. Particularly, since blood potassium levels may rise, potassium supplements or potassium-sparing diuretics should be monitored periodically for blood potassium concentration when used together. The use of this drug should be avoided during pregnancy, and if there are plans for pregnancy or if pregnancy is confirmed, consulting with a doctor is mandatory. In nursing mothers, as this drug can be transmitted through breast milk, it is recommended to either stop breastfeeding or discontinue the medication. Safety and efficacy in children under 18 years of age have not been established, so it is not recommended. Elderly patients over the age of 65 should start from a low dose, considering renal and liver function, and closely monitor their condition. Overdose may cause symptoms such as hypotension and tachycardia, requiring immediate medical attention.

Side effects

  • Drug hypersensitivity
  • hyperkalemia
  • decreased libido
  • dizziness
  • headache
  • orthostatic hypotension
  • drowsiness
  • paresthesia
  • diminished perception
  • syncope
Show 84 more
  • lightheadedness
  • palpitations
  • rapid heartbeat
  • hypotension
  • orthostatic hypotension
  • dyspnea
  • cough
  • nausea
  • vomiting
  • dyspepsia
  • diarrhea
  • constipation
  • dry mouth
  • upper abdominal pain
  • rash
  • urticaria
  • muscle tension
  • limb pain
  • low back pain
  • frequent urination
  • erectile dysfunction
  • peripheral edema
  • edema
  • pitting edema
  • fatigue
  • asthenia
  • facial swelling
  • decreased serum potassium
  • increased serum creatinine
  • increased serum uric acid
  • increased gamma-glutamyl transferase
  • decreased hemoglobin and hematocrit
  • cholelithiasis
  • female breast neoplasm
  • exacerbation of cerebral infarction
  • gum bleeding
  • chest pain
  • cold
  • increased CRP
  • fever
  • hemoptysis
  • excessive sneezing
  • rhinorrhea
  • laryngitis
  • arthritis
  • flank pain
  • generalized pain
  • hypoglycemia
  • weight loss
  • heartburn
  • gastroenteritis
  • shingles
  • diplopia
  • asthenia
  • angioedema
  • chronic malabsorption syndrome
  • rhabdomyolysis
  • acute renal failure
  • hair loss
  • itching
  • autoimmune hepatitis
  • angioedema
  • angioedema
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • flushing
  • fatigue
  • edema
  • palpitations
  • lightheadedness
  • headache
  • drowsiness
  • abdominal pain
  • nausea
  • gynecomastia
  • jaundice
  • elevated liver enzymes
  • leukopenia
  • thrombocytopenia
  • toxic epidermal necrolysis
  • hypotension
  • tachycardia
  • non-cardiogenic pulmonary edema

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture. It is important to maintain storage temperatures between 1 degree and 30 degrees Celsius.

Appearance and packaging

Appearance

Pale yellow round film-coated tablet

Package unit

30 tablets / box [(10 tablets / PTP × 3)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.